Albuterol MDI Essential Use Exemption To Be Discussed By Pulmonary Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Pulmonary-Allergy Drugs Advisory Committee will meet June 10 to consider the agency’s proposed rule removing the exemption for albuterol metered-dose inhalers containing chlorofluorocarbons.
You may also be interested in...
GlaxoSmithKline Flovent HFA Clears FDA
The CFC-free version of Flovent is approved for asthma in patients 12 years and older. The drug is the second HFA nasal steroid available.
GlaxoSmithKline Flovent HFA Clears FDA
The CFC-free version of Flovent is approved for asthma in patients 12 years and older. The drug is the second HFA nasal steroid available.
CFC Proposed Rule Goes To OMB
FDA’s regulation will likely set the stage for withdrawal of CFC-containing albuterol products.